Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide 2.4 mg) produce clinically significant weight loss and reduce major adverse cardiovascular events (MACE) in adults with obesity or overweight, regardless of diabetes status.
GLP-1 medications like semaglutide are highly effective for weight loss and heart health, even if you don't have diabetes. While injections are common, oral versions exist. Be aware that cost and side effects (like nausea) can make sticking with the treatment difficult, so discuss these barriers with your doctor early.
StrongSupportsVERY_HIGH confidence
Henry's trials firmly demonstrated weight-loss efficacy with weekly semaglutide 2.4 mg (STEP program)... There was a 20% risk of major adverse cardiovascular events (MACE) in a group of 17,604 overweight or obese people without diabetes who were randomized to the drug semaglutide 2.4 mg (vs. placebo).
Why this rating
The claim is supported by large-scale randomized controlled trials (STEP, SELECT, FLOW) cited in the text.
Source
GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives
Megha Pawar et al. · BioMed Target Journal · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →